Latest Chemomab Therapeutics News & Updates

See the latest news and media coverage for Chemomab. We track all announcements, press releases, and industry mentions in real time, all in one place.

Chemomab Therapeutics (Chemomab)

Clinical-stage biotechnology company developing fibro-inflammatory therapeutics

chemomab.com

Headquarters: Tel Aviv, Israel
Founded year: 2011
Company type: Public company
Number of employees: 20–50
Industry: Biotechnology & Medical Research

Last updated Today

Latest news about Chemomab Therapeutics (Chemomab)

In short: Chemomab entered a merger agreement with Scipher Medicine and progressed its lead candidate, nebokitug, into Phase 3 planning for PSC.

Company announcements

August 19 Chemomab

Chemomab reports Q2 2026 results and merger update

The company announced a definitive merger with Scipher Medicine valued at $150 million plus $30 million financing. Nebokitug advances toward a Phase 2 RA trial.

July 8 Chemomab

Chemomab announces merger agreement with Scipher Medicine to advance nebokitug

The combined company plans an AI-powered Phase 2 trial in rheumatoid arthritis using Scipher's platform.

May 14 Chemomab

Chemomab announced first quarter 2026 financial results

The company reported net loss of $1.8 million and provided updates on nebokitug clinical progress.

May 5 Chemomab

Chemomab announces nebokitug proteomic study results

Dr. Parvez Mantry presented dose-dependent reductions in inflammatory signatures at Digestive Disease Week. Data suggest benefits for PSC patients with IBD. Q1 2026 results release on May 14.

Media coverage

August 19 ScanX

Chemomab Q2 EPS $(0.24) misses $(0.15) estimate; cash drops to $6.7M

Chemomab Therapeutics reported a Q2 2026 EPS of $(0.24), missing estimates by 60% and showing a 33.33% increase in losses year-over-year. Cash reserves declined to...

July 8 The Globe and Mail

Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis

Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher’s AI...

June 2 TipRanks

Top Executive’s Sudden Stock Move Sends Chemomab Investors Scrambling - TipRanks.com

New insider activity at Chemomab Therapeutics ( ($CMMB) ) has taken place on June 1, 2026. Chemomab Therapeutics has reported an insider transaction by its...

May 14 Markets Insider

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

New Clinical and Translational Data Presented at Major Medical Meetings Further Confirms the Disease-Modifying Potential of Nebokitug in Primary ...

Never miss news about Chemomab

Track Chemomab and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Chemomab competitors & trending companies

Browse news for competitors to Chemomab and other trending companies.